| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
β-Amyloid Aggregation Guide (The following is our recommended protocol. This protocol is for reference only; please modify it according to your specific needs.) 1. Dissolve the solid Aβ peptide in cold hexafluoroisopropanol (HFIP). Incubate the peptide at room temperature for at least 1 hour to monomerize and randomize its structure. 2. Remove the HFIP by evaporation and store the resulting peptide in film form at -20 or -80°C. 3. Dissolve the resulting film in 5 mM anhydrous DMSO and then dilute it to an appropriate concentration and buffer (serum- and phenol red-free medium) using a vortex mixer. 4. Next, age the solution at 4–8°C for 48 hours. Then centrifuge the sample at 14000g for 10 minutes at 4–8°C; soluble oligomers are present in the supernatant. In experiments, the supernatant is diluted 10–200 times. The specific method depends on the downstream application.
|
|---|---|
| ln Vivo |
β-amyloid protein (1-42) (rat/mouse) (TFA) can induce Alzheimer's disease [4]. Induction of Alzheimer's disease [4] Background Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the abnormal accumulation of β-amyloid protein (Aβ) peptide. The oligomeric form of Aβ peptide is a key initiator of neurotoxicity in the pathogenesis of AD [4]. Specific modeling method Rats: Wistar • Male • Adult, weight 240-260 g Dosage: 1 μg/μL • Hippocampal injection • Single dose Note: (1) β-amyloid protein (1-42) TFA needs to be processed into oligomers before use. (2) Using a 1 μL Hamilton syringe, β-amyloid (1-42) TFA was bilaterally injected into the rat hippocampus at a rate of 0.1 μL/min at a volume of 1.0 μL. Modeling indices: Changes in indices: Decreased expression level of α7-nAChR gene, and increased mRNA expression levels of NMDA receptor 2A and -2B subunits. Behavioral: 15 days after injection, β-amyloid (1-42) TFA aggregates prolonged the rats' residence time and altered their behavioral responses.
|
| References |
|
| Molecular Formula |
C199H307N53O59S.XC2HF3O2
|
|---|---|
| Molecular Weight |
4418.02 (free acid)
|
| Related CAS # |
β-Amyloid (1-42), (rat/mouse)
|
| Sequence |
Asp-Ala-Glu-Phe-Gly-His-Asp-Ser-Gly-Phe-Glu-Val-Arg-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-AlaDAEFGHDSGFEVRHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
|
| SequenceShortening |
DAEFGHDSGFEVRHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
|
| Appearance |
White to off-white solid
|
| Synonyms |
Amyloid β-peptide (1-42) (rat/mouse) TFA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). 该产品溶液不稳定，请使用新鲜配制的工作溶液以获得最佳效果。 (2). 请将本产品存放在密封保护的环境中，避免受潮。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
